Foundation Medicine Wins FDA Approval for Breakthrough Cancer Test
- Posted by ISPE Boston
- On December 5, 2017
The FDA has approved the FoundationOne CDx (or F1CDx), a breakthrough cancer diagnostic test developed by Cambridge-based biotech Foundation Medicine. F1CDx detects gene mutations that may be found in any solid tumor. This information can be used by physicians to manage cancer patients. Moreover, it can be used as a companion diagnostic to identify patients […]
Read More